ANTH (Anthera Pharmaceuticals) Enterprise Value: $0.00 Mil (As of Aug. 22, 2026) ***

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Anthera Pharmaceuticals Enterprise Value?

Anthera Pharmaceuticals ANTH Enterprise Value is $0.00 Mil as of Aug. 22, 2026.

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Anthera Pharmaceuticals's Enterprise Value is $0.00 Mil. Anthera Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2018 was $-36.70 Mil. Therefore, Anthera Pharmaceuticals's EV-to-EBIT ratio for today is -0.00.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Anthera Pharmaceuticals's Enterprise Value is $0.00 Mil. Anthera Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2018 was $-36.30 Mil. Therefore, Anthera Pharmaceuticals's EV-to-EBITDA ratio for today is -0.00.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Anthera Pharmaceuticals's Enterprise Value is $0.00 Mil. Anthera Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2018 was $0.00 Mil. Therefore, Anthera Pharmaceuticals's EV-to-Revenue ratio for today is .

EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations. As of today, Anthera Pharmaceuticals's Enterprise Value is $0.00 Mil. Anthera Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2018 was $-31.95 Mil. Therefore, Anthera Pharmaceuticals's EV-to-OCF ratio for today is -0.00.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Anthera Pharmaceuticals's Enterprise Value is $0.00 Mil. Anthera Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2018 was $-31.95 Mil. Therefore, Anthera Pharmaceuticals's EV-to-FCF ratio for today is -0.00.

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Anthera Pharmaceuticals  (OTCPK:ANTH) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Anthera Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.003/-36.699
=-0.00

Anthera Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Anthera Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.70 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Anthera Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=0.003/-36.302
=-0.00

Anthera Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Anthera Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.30 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Anthera Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=0.003/0
=

Anthera Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Anthera Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

4. EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations.

Anthera Pharmaceuticals's EV-to-OCF for today is:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=0.003/-31.952
=-0.00

Anthera Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Anthera Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.95 Mil.

5. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Anthera Pharmaceuticals's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.003/-31.952
=-0.00

Anthera Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Anthera Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anthera Pharmaceuticals Enterprise Value Related Terms


Anthera Pharmaceuticals Enterprise Value Historical Data

* Premium members only.

The historical data trend for Anthera Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anthera Pharmaceuticals Enterprise Value Chart

Anthera Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.54 33.71 138.69 17.61 21.00

Anthera Pharmaceuticals Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.65 6.36 10.74 21.00 0.28

ANTH vs TIKRF, CAPS, AKAOQ: Enterprise Value Comparison

For the Biotechnology subindustry, Anthera Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anthera Pharmaceuticals Enterprise Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Anthera Pharmaceuticals's Enterprise Value falls into.



Anthera Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Anthera Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2017 is calculated as

Anthera Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2018 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Enterprise Value →
What does a Enterprise Value of $0.00 Mil mean?
Anthera Pharmaceuticals (ANTH) has a Enterprise Value of $0.00 Mil as of Aug. 22, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Anthera Pharmaceuticals and its competitors.
Is Anthera Pharmaceuticals' Enterprise Value too high?
Anthera Pharmaceuticals' current Enterprise Value is $0.00 Mil.
How does Anthera Pharmaceuticals' Enterprise Value compare to TIKRF and CAPS?
Anthera Pharmaceuticals' Enterprise Value of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Anthera Pharmaceuticals and its competitors. Anthera Pharmaceuticals's current Enterprise Value is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthera Pharmaceuticals stock overvalued right now?
Anthera Pharmaceuticals (ANTH) has a current Enterprise Value of $0.00 Mil. The current Enterprise Value is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Anthera Pharmaceuticals (ANTH), the current Enterprise Value is $0.00 Mil as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anthera Pharmaceuticals Business Description

Address 700 Milam, Suite 1300, Houston, TX, USA, 77002
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.